The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review

Terri R. Fried1,2*, John O’Leary1,3, Virginia Towle3, Mary K. Goldstein4,5, Mark Trentelange3, Deanna K. Martin1,3

1 Clinical Epidemiology Research Center, VA Connecticut Healthcare System, West Haven, Connecticut, United States of America, 2 Department of Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America, 3 Program on Aging, Yale School of Medicine, New Haven, Connecticut, United States of America, 4 Palo Alto Geriatrics Research Education and Clinical Center (GRECC), VA Palo Alto Health Care System, Palo Alto, Connecticut, 94304, United States of America, 5 Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California, 94305, United States of America

Abstract

Background: There are concerns about the potential for unintentional harms when clinical practice guidelines are applied to patients with multimorbidity. The objective was to summarize the evidence regarding the effect(s) of comorbidity on the outcomes of medication for an index chronic condition.

Methods: A systematic review was conducted of studies published in MEDLINE and Cochrane Trials before May 2012. The search strategy was constructed to identify articles indexed with “comorbidity” or a related term or by a given condition and one or more additional specified comorbid conditions. The search yielded 3252 articles, of which 37 passed the title/abstract screening process, and 22 were included after full-text review. An additional 23 articles were identified by screening the reference lists for included articles. Information was extracted on study design; population; therapy; comparison groups; outcome(s); main findings.

Findings: Indexing of articles was inconsistent, with no term for “multimorbidity,” and rare use of “comorbidity”. Only one article examined the effects of comorbidity per se, finding no benefit of tight control of DM among persons with high comorbidity, defined using a comorbidity index. The remainder examined pairs of conditions, the majority of which were post-hoc analyses of randomized controlled trials and which found no difference in outcomes according to whether a comorbid condition was present. Several demonstrated no difference or an increased risk of adverse outcome among persons with DM and tight control of HTN as compared to usual control. Several demonstrated lack of benefit of statins among persons with end-stage renal disease.

Conclusions: There is limited evidence regarding the effects of multiple comorbidities on treatment outcomes. The majority of studies demonstrated no effect of a single comorbid condition on outcomes. Additional studies examining a broad range of comorbidity are required, along with clear and consistent indexing to allow for improved synthesis of the evidence.

Introduction

Multimorbidity, or the co-existence of multiple diseases, is the most common chronic condition among adults. [1] There is increasing concern about the appropriateness of disease-based clinical practice guidelines to the care of the patient with multimorbidity. When applied to a theoretical patient, the many medications recommended by these guidelines result in the potential for adverse drug-drug and drug-disease interactions. [2] The likelihood of adverse drug events increases with the number of medications, [3] leading to questions about altered benefit/harm ratios associated with the prescription of multiple medications for patients with multimorbidity. [4] In addition, evidence about the benefits and harms of interventions from randomized controlled trials (RCTs) may not be generalizable to patients with multimorbidity. These patients are frequently excluded from the trials that form the evidence base for practice guidelines, and the trials have incomplete ascertainment of harms [4].

We sought to determine the extent of the evidence regarding the treatment of persons with multimorbidity by performing a systematic literature review. Although RCTs are generally considered to provide the highest quality evidence regarding treatment benefits, we elected to include both RCTs and observational studies because of the limitations of RCTs as applied to this population of patients and because of evidence that
Materials and Methods

Data Sources and Searches

Because “multimorbidity” is not a MeSH term, the search was constructed around the concept of “comorbidity” to address the following question: “Among persons age 65 years and older, what effect does the presence of comorbid conditions have on the benefits and/or harms of medical treatment for a specific index chronic condition?” The following databases were searched for relevant studies: MEDLINE (OvidSP 1946–May Week 5 2012, April 13, 2012); MEDLINE In-Process & Other Non-Indexed Citations (OvidSP, April 13, 2012); Cochrane Trials (Wiley, April 11, 2012). While there are medical subject headings (MeSH) for comorbidity, when we examined four key articles, we found that only one of the four articles was indexed using these terms. We therefore had to create search strategies to capture the concept of comorbidity. We did this by using search terms that consisted of a given condition and at least one other of a list of additional conditions (heart failure [HF], coronary artery disease [CAD], angina pectoris, stable angina, hypertension [HTN], chronic obstructive pulmonary disease, osteoarthritis, hyperlipidemias, chronic kidney disease [CKD], diabetes mellitus [DM]). We repeated this process, with each condition becoming the index condition, and the rest considered together as comorbid conditions, using controlled vocabulary terms and synonymous free text words. The search strategy was limited to cohort studies, randomized controlled trials, or decision support techniques (Appendix S1). We specified older age in our question because of the increasing prevalence of multimorbidity with age, [6] with the goal of identifying study populations with the broadest possible range of comorbid conditions.

Because of the large number of references resulting from this search, the first 100 abstracts were reviewed to determine whether the search strategy could be made more specific. We found that we had captured a large number of studies that examined appropriateness of a given therapy, with appropriateness determined according to whether the patient had a given condition rather than according to the outcome of therapy. We therefore reran the analysis excluding these studies. Because of our interest in medical therapies, we also excluded studies that focused on surgical interventions. The full strategy is shown in appendix S1.

Study Selection

We included articles that examined the outcomes of treatment for an index condition in the presence and absence of comorbidity. We also included articles that examined the outcomes associated with different intensity of treatment of an index condition in the presence of comorbidity, regardless of whether the treatment was explicitly defined. For example, we included articles examining outcomes according to different HgbA1C levels, regardless of whether the diabetic treatment was specified. We included articles that examined only the effect of a treatment for a given condition in the presence of comorbidity (e.g. there were no participants without the comorbid condition) when the effect of the treatment in the absence of the comorbidity is well established.

We excluded articles that examined surrogate outcomes, such as lab values. This exclusion was based on evidence that surrogate outcomes are frequently not accurate markers for clinically relevant outcomes and that studies examining surrogate outcomes may not capture relevant harms. [7] We did not exclude any clinically relevant outcomes, and planned to include studies examining quality of life outcomes, such as symptoms and function. In addition, it became apparent that the search strategy resulted in many articles with persons under the age of 65. Articles were therefore included if the study population included persons age 65 years or older, even if they also included younger persons. A total of 50 titles and/or abstracts were reviewed independently by three of the investigators (TRF, JRO, VT) to confirm uniformity in the process of excluding articles. The titles and/or abstracts of the remaining references were initially reviewed by one of two investigators (JRO, VT), and articles that were not excluded were re-reviewed by a third investigator (TRF) to achieve consensus regarding inclusion. Full text review was performed for these articles. The reference lists for the final set of articles identified by this search were also examined to identify additional articles meeting inclusion criterion.

Data Extraction and Quality Assessment

For each of the included studies, we extracted the following data elements: 1) study design; 2) study population, including index condition; 3) intervention; 4) comparison groups; 5) outcome; 6) main findings.

We did not perform quality assessments for the articles based on two considerations. First, for the reasons provided above, we included both RCTs and observational studies. This posed a challenge for doing quality assessment, since, on the one hand, observational studies are generally considered to provide lower quality evidence than are randomized controlled trials, [8] but, as discussed above, in the case of multimorbidity, randomized controlled trials may not enroll patients with representative comorbidity burden. It is therefore difficult to apply metrics across the two types of study design that reflect their relative quality as specifically related to the study question. Second, many studies consisted of post-hoc analyses of RCTs, so that the initial randomization no longer applied, and there are no established criteria to evaluate the extent to which this affects the quality of the study. Given these considerations, we concluded that the best representation of study quality was a description of the study design, as extracted from each of the studies.

Data Synthesis and Analysis

Because the large majority of studies examined treatment for an index condition among persons with or without a single comorbid condition, we organized studies according to the pairs of conditions being examined. Even within these groups, the heterogeneity in design, population, and interventions precluded combining the results in a meta-analysis.

Results

Identification of Articles

The literature search yielded 3252 articles. A total of 38 articles passed the title/abstract screening process. Full-text review resulted in the exclusion of 16 articles. Review of the reference lists for the remaining 22 articles resulted in the identification of an addition 23 articles, for a total of 45 (Figure 1).

Types of Studies Identified

Table 1 provides a description of the types of studies identified in the systematic review, including the approach to the analysis of comorbidity, conditions and outcomes examined, and study design. Only one of the studies examined the effect of comorbidity per se. [9] This study examined the cardiovascular outcomes associated with tight diabetic control among persons with different levels of comorbidity. The remaining 44 studies examined the
effects of treating an index condition in the presence or absence of a single other condition. The vast majority of these studies included DM as either the index or comorbid condition. The most common combinations of conditions examined were HF and DM (10 studies), [10–19] HTN and DM (9 studies), [20–28] and DM and CKD (10 studies) [29–38]. The studies examining HF and DM focused primarily on all-cause mortality among patients with HF who received treatment with beta blockers according to the presence or absence of DM. The majority of studies examining HTN and DM compared outcomes according to different intensities of HTN treatment, measured as the desired or achieved systolic and/or diastolic blood pressure. The studies examining CKD and DM primarily compared outcomes according to different intensities of diabetes treatment, measured as the achieved HgbA1C. An additional 5 studies examined DM and cardiovascular disease other than HF; these studies varied in terms of which was considered the index condition and which the comorbidity, the interventions, and outcomes [39–43].

A total of eight studies examined cardiovascular disease (HF, ischemic heart disease, or hyperlipidemia) and CKD [14,44–50]. A total of four studies examined a variety of miscellaneous disease combinations [41,51–53].

Across the different disease combinations, over one-half (55%) were conducted as post-hoc analyses of randomized controlled trials, in which patients with and without the comorbid condition were identified after study randomization, and the effect of the treatment was compared in these two groups. There were two studies that included only patients with both the index condition of hyperlipidemia or high cardiovascular disease risk and the comorbidity of CKD. These were randomized controlled trials in which patients were assigned to treatment with a statin versus a placebo. These studies assumed a well-established benefit of statins among patients with the index condition who did not have CKD. Only two studies examined differences in the likelihood of harm according to whether a comorbid condition was present; the remainder of the studies examined the likelihood of benefit. Of the studies examining benefit, only one examined functional outcomes; the remainder examined reduction in risk of mortality, hospitalization, or disease-specific outcomes, such as cardiovascular events.

### Study Findings

The majority of studies found no effect of comorbidity on the benefits or harms of therapy for an index condition. Of the 25 studies examining the benefit of therapy for a given condition according to whether comorbidity was present or absent, 23 found no difference or a greater benefit in the presence of the comorbidity (Table 2). The two studies examining the harm of therapy according to whether comorbidity was present or absent found no difference in harms. Results were more mixed for the 15 studies examining the benefit of tighter versus less tight control of one condition in the presence of a second. Of these, seven found tighter control was more beneficial than less tight control, six found tighter control was of no greater benefit or was harmful compared to less tight control, one found a U-shaped relationship, and one had different findings for different outcomes.

Table 3 provides a detailed description of the study results according to the study population, study design, intervention(s) examined, and comparison groups. The single study examining comorbidity per se and its effects on the treatment of DM demonstrated that for persons with low to moderate comorbidity, measured with a validated comorbidity index, achieving a HgbA1C ≤ 6.5% was associated with a decreased risk of cardiovascular events, but for persons with high comorbidity, achieving this HgbA1C level was not associated with decreased risk [9].

All but two of the ten studies examining the effect of DM on the treatment of HF with beta blockers concluded that there were no differences in outcomes according to the presence or absence of DM or greater risk reduction among patient with DM [10–17,19]. Figure 2 provides a graphical summary of the results for those studies presenting their outcomes in terms of a form of relative risk. One study reported a significant benefit of beta-blockers on all-cause mortality and cardiovascular outcomes among patients without DM with a hazard ratio (HR) of 0.78 (95% confidence interval [CI].65, .93) but no benefit among patients with DM with a HR of 1.04 (.80, 1.35). [11] The second study concluding that
there was a difference in all-cause mortality reported a non-significant effect of beta-blockers among patients with DM with a hazard ratio (HR) of .79 (95% confidence interval [CI].50, 1.20) and a borderline significant effect among patients without DM with a HR of .60 (.35, 1.01). [18] While another study also showed a significant effect among patients without DM and a non-significant effect among patients with DM, it concluded that there was no difference in benefit because of a non-significant “heterogeneity test for interaction.” [14].

Among the six studies examining intensity of HTN treatment in patients with DM, the definition of tight control changed over time, as did the study results. The United Kingdom Prospective

Table 1. Description of studies identified in systematic review.

| Approach to analysis of comorbidity: |   |
|-------------------------------------|---|
| Comorbidity index                   | 1 |
| Pairwise combinations of conditions | 44|
| Combinations of conditions*:        |   |
| Heart failure and diabetes mellitus | 10|
| Diabetes mellitus and hypertension  | 9 |
| Cardiovascular disease and diabetes | 5 |
| Diabetes mellitus and renal disease | 10|
| Cardiovascular disease and chronic kidney disease | 8 |
| Study design:                       |   |
| Randomized controlled trial         | 6 |
| Randomized controlled trial with post-hoc subgroup analysis | 25|
| Observational cohort study          | 14|
| Miscellaneous combinations          | 5 |
| Outcome(s) examined*:               |   |
| Mortality                           | 35|
| Disease-specific outcome (e.g. stroke, cardiovascular event) | 24|
| Hospitalization                     | 5 |
| Function/symptoms                   | 1 |
| Adverse effect                      | 2 |

* Total >45 because some articles examined more than one combination of conditions and/or more than one outcome.

doi:10.1371/journal.pone.0112593.t001

Table 2. Main study findings according to approach of article.

| Examination of benefit of therapy in presence or absence of comorbidity (n = 25): |   |
|---------------------------------------------------------------------------------|---|
| No difference in benefit                                                        | 19|
| Benefit greater in presence of comorbidity                                     | 4 |
| Benefit smaller or absent in presence of comorbidity                            | 2 |
| Examination of harm of therapy in presence or absence of comorbidity (n = 2):   |   |
| No difference in harm                                                           | 2 |
| Harm smaller or absent in presence of comorbidity                               | 0 |
| Harm great in presence of comorbidity                                          | 0 |
| Examination of benefit of tighter versus less tight control of one condition when second condition present (n = 15): |   |
| Tighter control more beneficial versus less tight control                       | 7 |
| Tighter control of no greater benefit or harmful versus less tight control      | 6 |
| U-shaped relationship, or different relationship for different outcomes         | 2 |
| Examination of benefit of intervention established as standard of care when comorbidity absent in the presence of comorbidity (n = 3): |   |
| Intervention beneficial                                                        | 1 |
| Intervention not beneficial                                                     | 2 |

doi:10.1371/journal.pone.0112593.t002
### Table 3. Studies identified in systematic review.

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings |
|--------------|------------------|------------|---------------------------------|-----------------------|
| **Diseases: HEART FAILURE AND DIABETES MELLITUS** | | | | |
| Bobbio, 2003 | Cohort N = 2,843 | Italian patients w/HF, mean ages 63–66 | Beta-blockers/with and w/o DM | All-cause mortality: no difference. |
| deBoer, 2010 | Post-hoc RCT N = 2,128 | Dutch patients ≥70 w/HF | Nebivolol (BB)/with and w/o DM | All-cause mortality and CV hospital admission: risk reduction greater in patients with DM. |
| Deedwania, 2005 | Post-hoc RCT N = 3,991 | European patients, ages 40–80 w/HF | Metoprolol CR/XL (BB)/with and w/o DM | All-cause mortality and hospitalization due to HF: no difference |
| Domanski, 2003 | Post-hoc RCT N = 2,708 | US patients, ages 19–93 w/HF | Bucindolol (BB)/with and w/o DM. | Death or HF hospitalizations: no difference. |
| Erdmann, 2001 | Post-hoc RCT N = 2,647 | European patients w/HF, mean age 61 | Bisoprolol/with and w/o DM | All-cause mortality: no difference. |
| MacDonald, 2008 | Post-hoc RCT N = 7,599 | European patients w/HF, mean ages 65–67 | Candesartan/with and w/o DM | All-cause mortality, CV morbidity and mortality: no difference. |
| Nodari, 2003 | Cohort N = 193 | Italian patients w/HF, mean ages 60 (w/DM) and 55 (w/o DM) | Carvedilol/with and w/o DM | NYHA functional class, exercise tests, and other hemodynamic parameters: no difference. |
| Ryden, 2000 | Post-hoc RCT N = 3,164 | International patients >55 w/HF | Lisinopril high vs. low dose/with and w/o DM | All-cause mortality: no difference. |
| Subramanian, 2009 | Cohort N = 412 | Veterans w/HF, mean ages 66–70 | Beta-blockers (cardioselective CSB)/with and w/o DM | All-cause mortality: no benefit for patients with DM; borderline significant benefit for patients without DM. |
| Torp-Pedersen, 2007 | Post-hoc RCT N = 3,029 | European patients w/HF, mean ages 61–64 | Carvedilol vs. metoprolol/with and w/o DM | All-cause mortality: no difference. |

**Diseases: DIABETES AND HYPERTENSION**

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings |
|--------------|------------------|------------|---------------------------------|-----------------------|
| ACCORD, 2010 (Cushman) | Factorial RCT N = 4,733 | DM pts ≥40 w/CVD or ≥55 w/atherosclerosis, albuminuria, LVH, or ≥2 risk factors for CVD | BP therapy/tight (<140 SBP) VS less tight (<140 SBP) BP control | Major cardiovascular event: no difference. All-cause or cardiovascular mortality: no difference. Significantly higher rate SAE (3.3% vs. 1.29%, p<.001), hyperkalemia, and elevated Cr in tight control group vs less tight group. |
| Berl, 2005 | Post-hoc RCT N = 1,715 | US patients, ages 30–70 w/DM, HTN, proteinuria | BP therapy/observed SBP ≤120 vs >120; DBP 10 mm Hg increments | All-cause mortality: increased risk with SBP<120. M: increased risk with lower DBP. Stroke: decreased risk with lower DBP. |
| Cooper-DelHoff, 2010 | Post-hoc RCT N = 6,400 | US patients, ≥50 w/stable CAD and DM | BP control/observed tight (SBP<130, usual SBP 130–139), uncontrolled (>140) | All-cause mortality: no difference during study f/u. 5-yr mortality: higher in tight control. |
| Curb, 1996 | Post-hoc RCT N = 4,736 | US patients, ≥60 w/HTN | Chlorthalidone (+atenolol or reserpine as needed)/with and w/o DM | All-cause mortality, non-fatal plus fatal stroke, nonfatal MI plus fatal CHD, major CHD events, major CVD events: risk reduction as great if not greater for persons with DM (no formal test for interaction) |
| Estacio, 2000 | RCT N = 470 | US patients, ages 40–74 w/DMM | Stepped BP therapy/DBP ≤70 vs. DBP 80–89 | CrCl, retinopathy, neuropathy: no difference. All-cause mortality: lower in tight control. |
| Hansson, 1998 | Stratified RCT N = 1,501 | European patients, ages 50–80 w/DM | Stepped BP therapy/DBP ≤90 vs. ≤85 vs. ≤80 | Major CV events: lower in tight control (significant difference ≤80 vs. ≤90). |
| Tuomilehto, 1999 | Post-hoc RCT N = 4,695 | European patients, ≥60 w/HTN | Nitrendipine (+others as needed)/with and w/o DM | All-cause mortality, mortality from cardiovascular disease, all cardiovascular events: greater risk reduction in patients with DM. |
| UKPDS, 1998 | RCT N = 1,148 | UK patients, ages 25–65 w/HTN & DM | BP therapy/tight (<150 SBP) vs. less tight (<180 SBP) BP control | All-cause mortality, M: no difference. Any DM-related endpoints, DM-related deaths, stroke, microvascular disease: lower in tight control. |
| Wang, 2000 | Post-hoc RCT N = 2,394 | Chinese patients, ≥60 w/HTN | Nitrendipine (+others as needed)/with and w/o DM | All-cause mortality, CV mortality, stroke, all cardiovascular events: no difference |

**Diseases: CARDIOVASCULAR DISEASE AND DIABETES**

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings |
|--------------|------------------|------------|---------------------------------|-----------------------|
| Berthet, 2004 | Post-hoc RCT N = 6,105 | International patients w/hx of CVA or TIA, mean ages 63–64 | ACE-inhibitor (+indapamide as needed)/with and w/o DM | Recurrent stroke: no difference. |
| Collins, 2003 | Post-hoc RCT N = 20,536 | UK patients, ages 40–80 w/CAD, PAD, or HTN. | Simvastatin/with and w/o DM | Coronary events and vascular events: no difference. |
| Komajda, 2010 | Post-hoc RCT N = 4,447 | International patients w/DM | Rosiglitazone/with and w/o CVD | Heart failure: no difference |
The Effect of Comorbidity on Chronic Disease Treatment Outcomes

Table 3. Cont.

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings (Differences between Groups) |
|--------------|-----------------|------------|--------------------------------|---------------------------------------------------|
| Shihora, 2008 | Post-hoc RCT N = 1,095 | Japanese patients with prior CVA or TIA | Cilostazol/with and w/o DM, HTN | Recurrent stroke: no difference. |
| Wernicke, 2009 | Post-hoc RCTs (pooled analysis) N = 1,024 | US patients ≥18 with diabetic peripheral neuropathy | Duloxetine/with and w/o CVD | Adverse events: no difference. |

**Diseases: DIABETES AND RENAL DISEASE**

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings (Differences between Groups) |
|--------------|-----------------|------------|--------------------------------|---------------------------------------------------|
| Hayashino, 2007 | Cohort N = 1,569 | Japanese patients with ESRD on HD, mean ages 58–64 | Glycemic control during stable, regular HD/Quntile of HgbA1C | All-cause mortality: top quintile of HgbA1C assoc w/increased risk compared to lowest quintile. |
| Kalantar-Zadeh, 2007 | Cohort N = 23,618 | US patients w/ESRD on HD, mean ages 60–63 | Glycemic control during stable regular HD/HgbA1C level | All-cause mortality: unadjusted analysis demonstrated lower HR with higher HgbA1C; adjustment resulted in higher HR as HgbA1C increased. |
| Lambers Heerspink, 2007 | Post-hoc RCT N = 10,640 | European patients with DM, mean age 65–68 | Perindopril-indapamide/w/o CKD and w/3 stages of CKD | Macrovascular events, cardiovascular death, all-cause mortality, cerebrovascular events, new or worsening nephropathy, renal death: no difference. |
| Mann, 2001 | Post-hoc RCT N = 980 | International patients >55 w/DM and cardiac risk factor | Ramipril/w/with and w/o CRI | CV death, MI or CVA (combined outcome): no difference. CV mortality, all-cause mortality, heart failure-related hospitalization: risk reduction greater in patients w/ CRI. |
| Morioka, 2001 | Cohort N = 150 | Japanese patients with ESRD and dialysis, mean age 60.5 | Glycemic control prior to start of dialysis/HgbA1C level | 1, 3, and 5-year mortality: Risk increased with higher HgbA1C. |
| Okada, 2007 | Cohort N = 78 | Japanese patients w/type 2 DM and ESRD, age ≥20, mean age 58 | Glycemic control prior to start of dialysis and during dialysis/HgbA1C level | All-cause mortality: no difference. |
| Oomichi, 2006 | Cohort N = 114 | Japanese patients w/ESRD on HD, ages 33–80, mean age 60.8 | Glycemic control during stable, regular dialysis/Good, fair, poor HgbA1C | 5-year mortality: Higher in those w/poor HgbA1C (≥8) than in those with fair (6.5–8) or good (<6.5) HgbA1C. |
| Shurraw, 2010 | Cohort N = 1,484 | Canadian patients receiving hemodialysis, mean age 66 | Glycemic control/HgbA1C level | All-cause mortality: no difference. |
| Shurr, 2011 | Cohort N = 23,296 | Canadian patients w/DM and CKD, mean age 65–73 | Glycemic control/HgbA1C level | All-cause mortality: U-shaped association: increased risk with <6.5% and >8.0%. |
| Williams, 2006 | Cohort N = 24,744 | US patients w/ESRD on HD, mean age 63.7 | Glycemic control during stable, regular dialysis/HgbA1C level | All-cause mortality: no difference. |

**Diseases: CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE**

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings (Differences between Groups) |
|--------------|-----------------|------------|--------------------------------|---------------------------------------------------|
| Baigent, 2011 | RCT N = 9,270 | European patients, ≥40 w/moderate-severe CKD | Simvastatin+ezetimibe vs. placebo* | 17% decrease in major CVD events with treatment; no difference in effect comparing patients with ESRD on dialysis and those with less severe CKD |
| Cohen-Solal, 2009 | Post-hoc RCT (prespecified group) N = 2,112 | European patients, >70 w/HF | Nebivolol/Tertiles of eGFR | All-cause mortality and CV hospitalizations: no difference. |
| Erdmann, 2001 | Post-hoc RCT N = 2,647 | European patients w/HF, mean age 61 | Bisoprostol/with and w/o CKD. | All-cause mortality: no difference. |
| Fellström, 2009 | RCT N = 2,776 | European patients, ages 50–80 w/ESRD on HD | Rosuvastatin vs. placebo* | CV death, non-fatal MI or non-fatal stroke: no risk reduction with rosuvastatin |
| McAlister, 2004 | Cohort N = 754 | Canadian patients w/HF, median age 69 | ACE-inhibitors and beta-blockers/with and w/o CKD (GFR <60) | All-cause mortality: no difference |
| Nakamura, 2009 | Post-hoc RCT N = 7,195 | Japanese patients, ages 40–70 w/HL | Pravastatin/with and w/o moderate CKD | CHD, stroke, CVD, all-cause mortality: risk reduction greater in moderate CKD than without moderate CKD. |
| Tonelli, 2004 | Post-hoc RCT N = 19,700 | International patients w/CAD or at high risk for CAD, mean ages 50–65 | Pravastatin/with and w/o moderate CKD | MI, coronary death, PTCA/surgical revascularization: no difference. |
| Wanner, 2005 | RCT N = 1,255 | European patients, ages 18–80 w/Type II DM w/ESRD on HD | Atorvastatin vs. placebo* | Composite of cardiac death, nonfatal MI, and stroke: no risk reduction with atorvastatin |

**MISCELLANEOUS DISEASE COMBINATIONS**

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings (Differences between Groups) |
|--------------|-----------------|------------|--------------------------------|---------------------------------------------------|
| Bavry, 2010 | Post-hoc RCT N = 22,576 | International patients, ≥50 w/HTN and stable CAD | BP lowering/with and w/o PAD | All-cause mortality, nonfatal MI and nonfatal CVA: more pronounced J-shaped curve for relationship of HTN and outcome among PAD compared to no PAD. |
Diabetes study (UKPDS), defining tight control as a systolic blood pressure (SBP) of <150 mmHg, versus less tight control as SBP <180 mmHg, demonstrated no difference in overall mortality associated with tight control but a decrease in any DM-related endpoints, DM-related deaths, stroke, or microvascular disease. [27] Later studies defining tight control as SBP <130 or <120 mmHg demonstrated either no difference in outcome or an increased risk of adverse outcome associated with tight control. [20,21,23] The results were less consistent when tight control was defined on the basis of diastolic blood pressure (DBP). Two studies defining tight control as DBP <30 mmHg and as <70 mmHg demonstrated benefits in terms of lower all-cause mortality and major cardiovascular events, [24,23] whereas a third study examining DBP in 10 mm increments demonstrated a decreased risk of stroke but increased risk of myocardial infarction associated with tighter control [20].

Of the five studies examining patients with cardiovascular disease and diabetes, three examined the effects of medications to reduce risk of vascular outcomes (ACE-inhibitor, simvastatin, and cilostazol) and found no differences according to the presence or absence of DM. [39–41] The remaining two studies examined the likelihood of harm associated with medication use among persons with DM with and without cardiovascular disease. These studies found no difference in adverse effects associated with duloxetine and no difference in the likelihood of heart failure associated with rosiglitazone.

The eight studies examining outcomes in patients with renal disease according to control of blood sugar in DM showed conflicting results. A total of three studies demonstrated an increased risk of mortality associated with higher HgbA1C levels, [29,33,35] whereas three other studies demonstrated no difference in survival, [34,37,38] and one study demonstrated a U-shaped association. [36] In one study, the unadjusted analysis demonstrated a lower risk of mortality with higher HgbA1C levels but the adjusted analysis demonstrated a higher risk, suggesting that HgbA1C levels may be a marker of underlying health status. [30]

The two studies examining the effects of ACE-inhibitors on cardiovascular outcomes among patients with DM demonstrated either no differences according to the presence or absence of CKD [31] or greater risk reduction among patients with renal disease [32].

Of the five studies examining a variety of medications among patients with cardiovascular disease, four demonstrated no difference in outcomes according to the presence or absence of

### Table 3. Cont.

| Author, Year | Study Design & N | Population | Intervention/Comparison Groups | Outcome/Main Findings (Differences between Groups) |
|--------------|-----------------|------------|--------------------------------|-----------------------------------------------|
| Du, 2009     | Post-hoc RCT N=11,140 | International patients, ≥55 w/DM and 1 additional CV risk | Perindopril+indapamide/w with and w/o AF | All-cause mortality, CV deaths, major coronary events, major cerebrovascular events, HF: no difference. |
| Greenfield, 2009 | Cohort N=2,613 | UK patients w/DM, mean ages 61–64 | Glycemic control/w/low-to-mod comorbidity (TIBI <12) vs. high comorbidity (TIBI ≥12) | CV events: HbA1c ≤6.5 associated with reduced risk in low CM but not mod-high CM. |
| Shinohara, 2008 | Post-hoc RCT N=1,095 | Japanese patients w/prior CVA or TIA | Cilostazol/w/ with w/o HTN | Recurrent stroke: no difference. |
| Sin, 2002    | Cohort N=11,942 | Canadian patients ≥65 w/HF | Beta-blockers/With and w/o IHD | All-cause mortality: no difference. |

RCT = randomized controlled trial.  
w/o = without.  
HF = heart failure.  
DM = diabetes mellitus.  
CV = cardiovascular.  
NYHA = New York Heart Association.  
LVH = left ventricular hypertrophy.  
CVD = cardiovascular disease.  
BP = blood pressure.  
HTN = hypertension.  
SBP = systolic blood pressure.  
SAE = serious adverse event.  
DBP = diastolic blood pressure.  
MI = myocardial infarction.  
CAD = coronary artery disease.  
CHD = coronary heart disease.  
CrCl = creatinine clearance.  
UK = United Kingdom.  
ACE = angiotensin converting enzyme.  
PAD = peripheral arterial disease.  
CVA = cerebrovascular accident.  
AF = atrial fibrillation.  
IHD = ischemic heart disease.  
ESRD = end stage renal disease.  
HD = hemodialysis.  
CKD = chronic kidney disease.  
PTCA = percutaneous transluminal coronary angioplasty.  
TIBI = Total Illness Burden Index.  
*No inclusion of patients without CKD and therefore no comparison between patients with and without CKD; study assumed established benefit of therapy in the absence of CKD.

doi:10.1371/journal.pone.0112593.t003
CKD. [14,45,47,49] The fifth, a study of pravastatin, demonstrated a decreased risk of a number of different outcomes among persons with moderate CKD but no decreased risk among persons with normal renal function or mild CKD, suggesting increased efficacy of the medication in the presence of CKD. [48] (Figure 3).

Of the three studies examining the efficacy of statins among persons with CKD without a comparison group of persons without CKD, one demonstrated a decreased risk of major cardiac events with treatment and found no difference when comparing patients with end-stage renal disease (ESRD) and those with less severe CKD. [44] The two other studies demonstrated no decreased risk of major cardio/cerebrovascular events with treatment among patients with ESRD receiving hemodialysis [46,50].

Of the four studies examining miscellaneous combinations of conditions, three demonstrated no difference in the efficacy of treatment according to the presence or absence of the comorbid condition. This included the use of perindopril-indapamide among persons with DM and one additional cardiovascular risk factor in the presence or absence of AF, [52] the use of cilostazol in persons with prior cerebrovascular accident or transient ischemic attack in the presence or absence of HTN, [41] and the use of beta blockers in persons with HF in the presence or absence of ischemic heart disease. [53] The final study examined the effect of the intensity of treatment of HTN in persons with CAD in the presence or absence of PAD. This study found a J-shaped relationship between blood pressure and outcomes among persons with PAD, such that lower blood pressure was associated with increased risk, but no such relationship among persons without PAD [51].

### Discussion

This systematic review was undertaken to address the question of how the presence of comorbid conditions affects the benefits and harms of medical treatment for an index chronic condition. The process of the review revealed that there is virtually no evidence regarding the effect of comorbidity per se, as the review identified only one study that characterized patients according to their burden of comorbid illnesses. Instead, the evidence consists of studies of pairs of conditions, in which investigators examine the effect of therapy in the presence or absence of a single comorbid condition. There is also little evidence regarding harms of treatment, as the vast majority of studies focused on examining benefit only. In addition, benefit was narrowly defined in terms of reducing the risk of mortality and other major disease-specific outcomes. Studies focused on a limited range of pairs, consisting of a combination of cardiovascular disease (HF and HTN), DM, and CKD. Few studies were originally designed to address the question of the effect of comorbidity on treatment of an index condition. The majority of studies demonstrated that the presence of a comorbid condition did not reduce the benefits associated with treatment of the index condition. The exceptions to this were the findings that patients with a high burden of comorbidity do not derive the same benefit from tight diabetic control as patients with a lower comorbidity burden, that patients with DM do not benefit

![Figure 2. Risk Reduction Associated with Medication for Treatment of Heart Failure. doi:10.1371/journal.pone.0112593.g002](image-url)
from tight control of HTN, and that patients with ESRD do not derive the same benefit from treatment with statin therapy as patients without ESRD.

This systematic review was motivated by concern raised in the literature about the unintended adverse consequences of treating patients with multimorbidity. This concern arises from the finding that treating patients with multimorbidity according to current disease-specific guidelines can result in polypharmacy with the potential for numerous drug-drug and drug-disease interactions. Moreover, polypharmacy itself has been associated with adverse outcomes, including falls, weight loss and balance impairment, and hospitalization. However, the existing literature does not address this patient population. Despite an extensive search, we found only one study that examined burden of comorbidity as a potential modifier of the effect of treatment. “Multimorbidity” is not an indexing term, and, while “comorbidity” is a term, it was infrequently used, so that it proved difficult to construct a search addressing our question of interest. With the growing attention being paid to the study of multiple medical conditions, there is a need for a clear and consistent approach to indexing future studies in order to facilitate the ability to synthesize evidence as it becomes available.

The great majority of studies examined either mortality or disease-specific outcomes, such as cardiovascular events. Disease-specific outcomes cannot be applied across individual diseases to facilitate treatment decision making that takes into account the net effect of an intervention on the health of a patient with multimorbidity, and universal outcomes that are applicable across diseases such as quality of life, physical function, or symptom reduction may be more important to these patients. Moreover, studies did not examine time to benefit, a parameter particularly important for patients with multimorbidity because of their competing mortality risks.

The studies conducted as post-hoc analyses of randomized controlled trials are subject to the same limitations of their patient population as the original studies. The patients eligible for and participating in cardiovascular intervention studies are generally healthier and with fewer comorbid conditions than are patients who do not enroll in these studies. There is evidence that these differences influence the benefits and harms of therapies. For example, the RALES RCT demonstrating the effectiveness of spironolactone in reducing hospitalization and mortality among patients with advanced HF had very low rates of adverse events. The publication of the trial was followed by a marked increase in the use of spironolactone, and, among older persons who were taking ACE-inhibitors, this increase was accompanied by a substantial rise in the rates of hospitalization and mortality from hyperkalemia.

Because of the lack of studies examining comorbidity, our review ended up addressing the question of whether, among a limited spectrum of diseases, the presence of a second condition affects the benefits or harms of treatment for a first. While, for many pairs of conditions (DM and HF, DM and CKD, DM and CVD), the answer to this question appears to be “no,” there was
some evidence to suggest that the presence of a second condition can alter the outcomes of therapy. The finding of an increased risk of adverse outcome among patients with DM receiving tight blood pressure control illustrates an evolution in the approach to the treatment of HTN among diabetic patients. Recommendations published in 2003 included the statement that “there is no threshold value for blood pressure, and risk continues to decrease well into the normal range,” [63] suggesting the lower the blood pressure, the better the outcomes. Recommendations published in 2013 call for treatment to a systolic blood pressure of <140, reserving treatment to lower targets for select populations, such as younger ones. [64] While these recommendations appear to be supported by the results of this systematic review, it is also worth noting that many disease management guidelines for DM also recommend different targets for HgbA1C according to comorbidities, ranging from 7% to 8%. Aside from the one study demonstrating a lack of benefit for patients with high comorbidity burden achieving a HgbA1C of <6.5%, our review did not identify any studies supporting these recommendations.

Our review has several limitations. First, because of the difficulty in constructing an effective search strategy, we found a relatively large proportion of our studies through review of the reference lists of articles identified in the search. This suggests that we may have missed relevant articles. Second data to inform our study question may exist that was not available in the articles we reviewed. For example, we identified two meta-analyses of studies examining the effect of DM on the treatment of HF. In our review of the articles referenced in the meta-analyses, we failed to find any subgroup analysis examining outcomes according to the presence or absence of DM. This suggests that the authors of the meta-analyses obtained additional data from the investigators of the original studies.

### References

1. Tinetti ME, Fried TR, Boyd CM (2012) Designing health care for the most common chronic condition-multimorbidity. JAMA 307: 2493–2494.
2. Boyd CM, Darer J, Boult C, Fried LP, Boult L, et al. (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294: 716–724.
3. Gandhi TK, Weingart SN, Borry J, Seger AC, Peterson J, et al. (2003) Adverse drug events in ambulatory care. N Engl J Med 348: 1356–1364.
4. Tinetti ME, Bogardus ST Jr, Agostini JV (2004) Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 351: 2870–2874.
5. Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 1807–1809.
6. Vogelz C, Shields A, Lee T, Gibson T, Marder W, et al. (2007) Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med 22: 391–395.
7. D’Agostino RB (2000) Debate: The slippery slope of surrogate outcomes. Curr Control Trials Cardiovasc Med 1: 76–79.
8. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 334: 1591–1596.
9. Greenﬁeld S, Billimke J, Pellegrini F, Franciosi M, De Berardis G, et al. (2009) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J 30: 1887–1892.
10. Gandhi TK, Weingart SN, Borry J, Seger AC, Peterson J, et al. (2003) Adverse drug events in ambulatory care. N Engl J Med 348: 1356–1364.
11. MacDonald MR, Petrie MC, Varyani F, O¨ stergren J, Michelson EL, et al. (2009) Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 31: 1967–1978.
12. Subramanian U, Kamaladevi M, Tenkit MB, Eckert GJ, Sawaada S (2009) Do cardiosective beta-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure? Am J Cardiol 103: 231–240.
13. Domanski M, Krause-Steinrauf H, Deebwana P, Pollmann D, Ghali JK, et al. (2003) The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42: 914–922.
14. Favour E, Lechat P, Verkerke P, Wiermann H (2001) Results of post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur Heart J 31: 469–479.
15. MacDonald MR, Petrie MC, Vaynaa F, Oabbrgen J, Michelson EL, et al. (2009) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. An analysis of the Candesartan in Heart Failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 31: 1377–1385.
16. Nodari S, Metra M, Dei Cas A, Dei Cas L (2003) Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail 5: 800–809.
17. Ryden L, Armstrong PW, Cleland J, Horowitz JD, Massie B, et al. (2000) Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 31: 1967–1978.

### acknowledgments

We would like to thank Janis Glover, MLS, for her assistance in designing and conducting the Medline search.

Views expressed are those of the authors and not necessarily those of the Department of Veterans Affairs.

### author contributions

Conceived and designed the experiments: TRF. Performed the experiments: TRF JRO VT. Analyzed the data: TRF MG MT DKM. Contributed to the writing of the manuscript: TRF MG DKM.
24. Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 Suppl 2: B34–64.

25. Hanson L, Zanchetti A, Carruthers SG, Daldof B, Elnsfeldt D, et al. (1996) Effects of intensive blood-pressure lowering and Ann Arbor aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet 351: 1755–1762.

26. Tuomilehto J, Rastenyte D, Birkenhager VH, Thijs I, Antikainen R, et al. (1996) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340: 677–684.

27. U. K. Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 33. BMJ 317: 703–713.

28. Wang JG, Staessen JA, Gong L, Liu L (2000) Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (SYST-China) Investigators. Arch Intern Med 160: 1161–1170.

29. Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, et al. (2007) Diabetes, glycemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 50: 1170–1177.

30. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jin J, Shaverberger CS, et al. (2007) AIC and survival in maintenance hemodialysis patients. Diabetes Care 30: 1049–1055.

31. Lambers Heerspink HJ, Nissinen M, Perkovic V, Woodward M, Zoungas S, et al. (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31: 2089–2096.

32. Mann JFEMD, Gerstein HCMD, Pogue JM, Bosch JMA, Yusuf SMD, et al. (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Blood Press 13: 7–13.

33. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, et al. (2001) Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24: 909–913.

34. Ohashi T, Nakao T, Matsumoto H, Shimo T, Nagaoka Y, et al. (2007) Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Medicine 46: 807–814.

35. Oommen T, Ebno M, Tabata T, Morioka T, Tsujimoto Y, et al. (2006) Impact of glycemic control on survival of diabetic patients on chronic hemodialysis: a 7-year observational study. Diabetes Care 29: 1496–1500.

36. Shurrav S, Hennemüller B, Lin M, Majumdar SR, Klarenbach S, et al. (2011) Association between cardiovascular outcomes and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 171: 1920–1927.

37. Shurrav S, Majumdar SR, Thaldrani R, Wiebe N, Tonelli M, et al. (2010) Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 55: 875–884.

38. Williams ME, Lascon E Jr, Teng M, Ofotun H, Lazarus JM (2006) Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 70: 1503–1509.

39. Berthet K, Neale BC, Chalmers JP, MacIntyre SW, Bousser MG, et al. (2004) Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 13: 7–13.

40. Collins R, Armitage J, Parini S, Sloth P, Petro R (2003) MRC/PHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 patients with diabetes: a randomised placebo-controlled trial. Lancet 363: 2005.

41. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, et al. (2008) Antiplatelet effects of cilostazol treatment of diabetic peripheral neuropathic pain between patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181–2192.

42. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Bohm M, et al. (2009) Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 11: 672–680.

43. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, et al. (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–1407.

44. Baigent C, Landray MJ, Reed C, Emberson J, Wheeler DC, et al. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181–2192.